You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 142 No. 6, June 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Evidence-Based Dermatology: Research Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Viral Infections
 •Oncology
 •Skin Cancer
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Breakthrough in the Treatment of Warts?

Sam Gibbs, MD

Arch Dermatol. 2006;142:767-768.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Treatment of skin papillomas with topical {alpha}-lactalbumin–oleic acid
Gustafsson L, Leijonhufvud I, Aronsson A, Mossberg AK, Svanborg C
N Engl J Med. 2004;350:2663-2672

Question: Is {alpha}-lactalbumin–oleic acid (also known as HAMLET [human {alpha}-lactalbumin made lethal to tumor cells]) effective as a treatment for cutaneous viral warts?

Design: A randomized, placebo-controlled double-blind trial converting to an open label study after 3 months.

Setting: University dermatology department in Lund, Sweden.

Patients: Forty adults and children with refractory warts (defined as "papillomas resistant to conventional treatments"). Nine of the 40 patients were receiving immunosuppressive drugs.

Intervention: An aqueous solution of 0.7mM {alpha}-lactalbumin–oleic acid was applied to all lesions and occluded with a hydrocolloid dressing daily for 3 weeks. An identical-appearing solution of normal saline was used for patients in the placebo arm. In the much longer open-label phase of the trial, 34 patients received a further 3 weeks . . . [Full Text of this Article]

Comment


AUTHOR INFORMATION
Ipswich Hospital, Ipswich, England



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence-Based Dermatology: Some Problems With Research
Sladden
Arch Dermatol 2006;142:1650-1653.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.